University of California, San Francisco

ABVC BioPharma Provides Vitargus® Update

Retrieved on: 
Thursday, August 18, 2022 - 1:30pm

FREMONT, CA, Aug. 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that, on August 2, 2022, approval was received from the Ethics Committee (EC) of the Ramathibodi Hospital, Mahidol University to conduct the Vitargus Phase II Study Protocol (ABV-1701-02). This follows a similar approval received on July 18, 2022, by Srinagarind Hospital, Khon Kaen University of Thailand.

Key Points: 
  • In parallel, Vitargus Phase II Study protocol documents have been submitted to the Australian Bellberry Human Research Ethics Committee (HREC).
  • ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development.
  • For Vitargus, the company intends to conduct the clinical trials through Phase III at various locations throughout the globe.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Odylia Therapeutics Announces Appointment of Two New Members to Board of Directors

Retrieved on: 
Thursday, August 18, 2022 - 1:00pm

Dr. Walker joins the Board from Sanofi, where she serves as Senior Counsel, Vaccines Patents.

Key Points: 
  • Dr. Walker joins the Board from Sanofi, where she serves as Senior Counsel, Vaccines Patents.
  • She has more than 15 years of experience in intellectual property and other legal matters in the healthcare sector.
  • Odylia is a nonprofit biotech focused on bringing life-altering and lifesaving treatments to those with rare diseases.
  • We partner with the patient community, researchers, clinicians, and financial donors to bring promising therapeutics to clinical trials.

Interoperability Champion Steven Lane, MD, MPH, Joins Health Gorilla as Chief Medical Officer

Retrieved on: 
Tuesday, August 16, 2022 - 4:00pm

Mountain View, California, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Health Gorilla, a leading Health Information Network and interoperability provider, announced today it has appointed Steven Lane, MD, MPH, former Clinical Informatics Director at Sutter Health, as Chief Medical Officer (CMO).

Key Points: 
  • Mountain View, California, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Health Gorilla, a leading Health Information Network and interoperability provider, announced today it has appointed Steven Lane, MD, MPH, former Clinical Informatics Director at Sutter Health, as Chief Medical Officer (CMO).
  • I am very excited to see TEFCA implemented and to join Health Gorilla in their journey to serve as one of the first Qualified Health Information Networks.
  • Steven is one of the nations leading experts on health data interoperability, privacy, and policy, and I am absolutely thrilled to have him join our team, said Steve Yaskin, Chief Executive Officer and co-founder of Health Gorilla.
  • Founded in 2014, Health Gorilla is a National Health Information Network (HIN) and interoperability platform providing permitted access to actionable patient data.

Highly Regarded Pediatric Neurologist, Dr. Brian Tseng, Joins NDA Partners as Expert Consultant

Retrieved on: 
Tuesday, August 16, 2022 - 1:15pm

WASHINGTON, Aug. 16, 2022 /PRNewswire-PRWeb/ -- NDA Partners' General Manager, Eric Fish, announced today that Brian Tseng, MD, PhD, a board-certified pediatric neurologist and neuromuscular specialist with more than 12 years of pharmaceutical industry experience, has joined the company as an Expert Consultant. Dr. Tseng's experience includes translational medicine, global clinical development, regulatory submissions, health authority interactions, first-in-human and first-in-pediatric clinical studies, gene therapy and orphan/accelerated drug development for small and large molecules and cell and AAV delivered gene modalities including CRISPR-mediated gene editing.

Key Points: 
  • NDA Partners' General Manager, Eric Fish, announced today that Brian Tseng, MD, PhD, a board-certified pediatric neurologist and neuromuscular specialist with more than 12 years of pharmaceutical industry experience, has joined the company as an Expert Consultant.
  • WASHINGTON, Aug. 16, 2022 /PRNewswire-PRWeb/ -- NDA Partners' General Manager, Eric Fish, announced today that Brian Tseng, MD, PhD , a board-certified pediatric neurologist and neuromuscular specialist with more than 12 years of pharmaceutical industry experience, has joined the company as an Expert Consultant.
  • Prior to Vertex, he was Vice-President and Global Head of the Pediatrics Therapeutic Area and Pediatric Center of Excellence with Novartis Pharmaceuticals.
  • Services include product development and regulatory strategy, product development program design and management, expert consulting, functional teams, project-based solutions, and clinical trial design and management.

Bay Area Lyme Foundation Selects National Winners of the 2022 Emerging Leader Awards Aimed at Making Lyme Disease Easy to Diagnose and Simple to Cure

Retrieved on: 
Tuesday, August 9, 2022 - 4:45pm

Both of the award winners will utilize biological samples from the Lyme Disease Biobank , a program of Bay Area Lyme Foundation lead by principal investigator Liz Horn, PhD, MBI, to collect well-characterized human tissue, blood, and urine specimens to accelerate research for Lyme disease and other tick-borne infections.

Key Points: 
  • Both of the award winners will utilize biological samples from the Lyme Disease Biobank , a program of Bay Area Lyme Foundation lead by principal investigator Liz Horn, PhD, MBI, to collect well-characterized human tissue, blood, and urine specimens to accelerate research for Lyme disease and other tick-borne infections.
  • Developing sensitive and specific diagnostics for acute and persistent Lyme disease should be the highest priority in Lyme disease research.
  • Bay Area Lyme Foundation , a national organization committed to making Lyme disease easy to diagnose and simple to cure, is the leading public not-for-profit sponsor of innovative Lyme disease research in the US.A 501c3 charity based in Silicon Valley, Bay Area Lyme Foundation collaborates with world-class scientists and institutions to accelerate medical breakthroughs for Lyme disease.
  • The Lyme Disease Biobank (LDB), a program of the Bay Area Lyme Foundation, is working to accelerate research of Lyme disease and other tick-borne infections.

Movano Ring Exceeds Accuracy Targets for SpO2 and Heart Rate Monitoring in Initial Hypoxia Study; Company Eyes FDA Submission

Retrieved on: 
Tuesday, August 9, 2022 - 2:00pm

PLEASANTON, Calif., Aug. 9, 2022 /PRNewswire/ -- Movano Inc. (NASDAQ: MOVE), a purpose-driven healthcare solutions company at the intersection of medtech and consumer devices, announces today the successful completion of a study with the University of California San Francisco (UCSF) to assess the accuracy of the Movano Ring's blood oxygen saturation (SpO2) and heart rate data. With results that exceeded the requirements of the industry standard used by FDA for evaluating SpO2 devices, this successful study is a promising step toward the company's goal to provide medically-validated data to consumers and healthcare professionals.

Key Points: 
  • The prototype also measured heart rate during this time and participants' heart rate varied from 60 to 120 beats per minute as they were being deprived of oxygen.
  • In addition, the Ring also estimated heart rate with accuracy commensurate with the FDA's standards.
  • As Movano eyes its first FDA submission, validating the device's ability to measure blood oxygen levels, heart rate and other vitals is a top priority for the company.
  • This hypoxia study is a promising display of the quality metrics our ring can deliver," said John Mastrototaro, CEO of Movano.

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

Retrieved on: 
Saturday, August 6, 2022 - 1:50am

MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

Key Points: 
  • MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.
  • MYFEMBREE is available immediately to patients with moderate to severe pain associated with endometriosis with a prescription from their healthcare provider.
  • Myovant and Pfizer also are committed to supporting women in the U.S. who are prescribed MYFEMBREE throughout their treatment journeys.
  • Food and Drug Administration for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

California Northstate University College of Pharmacy Ranked #6 Among all Pharmacy Schools in California

Retrieved on: 
Friday, August 5, 2022 - 3:51pm

ELK GROVE, Calif., Aug. 5, 2022 /PRNewswire/ -- California Northstate University College of Pharmacy has been ranked #6 among all fourteen pharmacy schools in California based on current American Association of Colleges of Pharmacy (AACP) rankings for NIH research funding. Out of 143 pharmacy schools in the U.S., California Northstate University College of Pharmacy is now ranked #73 after being ranked #103 last year.

Key Points: 
  • The College of Pharmacy ranked #73 out of 143 pharmacy schools in the U.S.
    ELK GROVE, Calif., Aug. 5, 2022 /PRNewswire/ -- California Northstate University College of Pharmacy has been ranked #6 among all fourteen pharmacy schools in California based on current American Association of Colleges of Pharmacy(AACP) rankings for NIH research funding.
  • Out of 143 pharmacy schools in the U.S., California Northstate University College of Pharmacy is now ranked #73 after being ranked #103 last year.
  • "Among pharmacy schools in Northern California specifically, California Northstate University College of Pharmacy is ranked second, just after University of California San Francisco," said Dr. Xiaodong Feng, Dean of California Northstate University College of Pharmacy.
  • "At the California Northstate University College of Pharmacy, we are committed to advancing the art and science of pharmacy through research," said Dr. Ruth Vinall, California Northstate University College of Pharmacy Associate Professor and Assistant Dean of Research.

AMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS

Retrieved on: 
Wednesday, August 3, 2022 - 9:05pm

THOUSAND OAKS, Calif., Aug. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of Michael V. Drake, M.D., to its Board of Directors, effective immediately.

Key Points: 
  • THOUSAND OAKS, Calif., Aug. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of Michael V. Drake, M.D., to its Board of Directors, effective immediately.
  • Dr. Drake will also serve as a member of the Board's Corporate Responsibility and Compliance Committee and its Governance and Nominating Committee.
  • Following the appointment of Dr. Drake, the Board will be composed of 13 directors, 12 of whom are independent.
  • Dr. Drake received his undergraduate degree from Stanford University and his medical doctorate from the University of California, San Francisco.

Unlimited Sciences Announces Groundbreaking New Study to Observe Ayahuasca’s Effects on Trauma

Retrieved on: 
Tuesday, August 2, 2022 - 3:03pm

Unlimited Sciences , a psychedelic research nonprofit, today announces a seminal new observation research study that will measure the potential healing effects of ayahuasca on individuals with past experiences of trauma.

Key Points: 
  • Unlimited Sciences , a psychedelic research nonprofit, today announces a seminal new observation research study that will measure the potential healing effects of ayahuasca on individuals with past experiences of trauma.
  • To fund the groundbreaking endeavor, Unlimited Sciences kicked off a GoFundMe campaign to raise the necessary $50,000 to conduct the study.
  • Current therapeutic options may be insufficient to meet the increasing needs of a growing number of individuals presenting with symptoms of trauma.
  • Alternative treatment options are desperately needed, and ayahuasca has been identified as a candidate therapy for the treatment of trauma.